Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome
Status:
Completed
Trial end date:
2020-05-10
Target enrollment:
Participant gender:
Summary
COVID-19 infection is overwhelming Italian healthcare. There is an urgent need for a solution
to the lack of ICU beds and increasing deaths day after day.
A recent retrospective Chinese paper (JAMA Intern Med, online March 13, 2020) showed
impressive positive effect of methylprednisolone (MP) on survival of SARS-CoV-2 critically
ill patients. Moreover, the Italian Infectious Disease leading institution guidelines for
COVID-19 clinical management included as an option for patients with "incipient worsening of
respiratory functions" methylprednisolone treatment at an approximate dose of 80mg.
The main objective of this multi-centre observational trial is to analyse the association of
low dose prolonged infusion of methylprednisolone (MP) for patients with severe acute
respiratory syndrome with composite primary end-point (ICU referral, need for intubation,
in-hospital death at day 28).